Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells
Cancers · 31.01.2023 · 15 (3) · 902
DOI: 10.3390/cancers15030902 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 31.01.2023. Verfasst von Satish Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Clinical and Translational Research Center, Division of Allergy, Immunology and Rheumatology, Jacobs School of Medicine and B…. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaleida Health Foundation, National institute of Health.
Abstract (Originalsprache)
The standard of care chemotherapy drug presently used to treat castration-resistant prostate cancer (CRPC), docetaxel (Doc), also develops chemoresistance, thereby reducing its clinical utility. Since resistance to chemotherapy drugs can be overcome by co-treatment with plant-based bio-active compounds we undertook the present study to evaluate if quercetin (Que), a flavonoid present in plants such as onions, apples, olives, and grapes can enhance the efficacy of Doc. We studied the separate and combined effects of Que and Doc at different doses and different combination approaches in two different prostate cancer cell lines, DU-145 (moderately aggressive) and PC-3 (very aggressive), and assessed the effects of these combinations on viability, proliferation, and apoptosis. Monotherapy with these drugs showed dose-dependent cytotoxicity; however, only Doc monotherapy showed a statistically significant difference in IC50 levels (IC50 = 4.05 ± 0.52 nM for PC-3 and IC50 = 2.26 ± 0.22 nM for DU-145). In combination treatment, we used three different treatment approaches (TAP). The concentrations and range analyzed were chosen based on the approximate cytotoxicity of 30–50% when the drugs were used individually. Our observations indicate that the most beneficial effect of the Que and Doc combination was obtained with the TAP-2 approach, which is pre-treatment with all doses of Que for 24 h followed by low doses of Doc for another 24 h. Using this approach, we observed synergism at low concentrations of Doc (0.5 and 1.0 nM) and all concentrations of Que. An additive effect was observed at moderate and high concentrations of Doc (1.5, 2.0, and 2.5 nM) and all concentrations of Que in both cell lines. The TAP-2 strategy was also helpful in overcoming Doc resistance in resistant CaP cells. In summary, Que improved the therapeutic effect of Doc in CRPC, and it is proposed that this improvement is mediated through multiple mechanisms. This study provides a novel therapeutic modality for an effective combination using Doc and Que to enhance the efficacy of Doc in an innocuous manner for Doc resistance and CRPC treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Clinical and Translational Research Center, Division of Allergy, Immunology and Rheumatology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA.
- Department of Urology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA.
ORCID-Profile: Stanley A Schwartz, Ravikumar Aalinkeel
Förderung
- Kaleida Health Foundation
- National institute of Health
Zitieren
APA
Sharma, S., Cwiklinski, K., Mahajan, S. D., Schwartz, S. A., & Aalinkeel, R. (2023). Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells. Cancers, 15(3), 902. https://doi.org/10.3390/cancers15030902
Vancouver
Sharma S, Cwiklinski K, Mahajan SD, Schwartz SA, Aalinkeel R. Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells. Cancers. 2023;15(3):902. doi:10.3390/cancers15030902
BibTeX
@article{Sharma2023,
author = {Sharma, Satish and Cwiklinski, Katherine and Mahajan, Supriya D and Schwartz, Stanley A and Aalinkeel, Ravikumar},
title = {Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells},
journal = {Cancers},
year = {2023},
volume = {15},
number = {3},
pages = {902},
doi = {10.3390/cancers15030902}
}
EUVIMED